20
Dec, 2020
Cheaper HIV treatment for children: a report in The Lancet
A new pricing agreement will bring the cost of treatment for children with HIV down from US$480 to less than $120.
Study update
10
Dec, 2020
Cascade of care in children and adolescents with HIV in the Russian Federation
The Cascade of Care, more commonly known as the HIV care continuum, is a calculation of how many people in a specific population diagnosed with HIV are initially linked to care, retained in care and have achieved viral suppression. It is an important tool in measuring success in controlling the HIV infection, identifying gaps in national HIV/AIDS strategies and set directions to improve care. On behalf of EPIICC and REACH researchers, Anna Turkova presented on the Cascade of Care of HIV positive children and adolescents in three Russian centres at […]
10
Dec, 2020
Cascade of care in children and adolescents with HIV in Russian Federation
Author: Anna Turkova, Evgeny Voronin, Yulia Plotnikova, Anna Samarina, Edith Milanzi, Vladimir Rozenberg, Liubov Okhonskaia, Inga Latysheva, Aleksey Plynsky, Elena Fertikh, Siobhan Crichton, Charlotte Jackson, Ali Judd, Intira J Collins, on behalf of the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Published in: 12th International Workshop on HIV Pediatrics View Poster Background: The cascade of care summarises the 90-90-90 UNAIDS targets, of 90% of HIV+ people knowing their status, of whom 90% receive antiretroviral treatment (ART), of whom 90% are virally suppressed By 2019, there were 1,068,839 people […]
4
Dec, 2020
Pediatric dolutegravir (DTG) dosing recommendations derived from combined P1093 and ODYSSEY Population Pharmacokinetic analysis
Authors: Singh R, Baker M, Thapar M, Gibb D, Turkova A, Ford D, Ruel T, Wiznia A, Farhad M, Alvero C, Green J, Bollen P, Colbers A, Burger D, Acosta E Published in: 12th International Workshop on HIV Pediatrics View Abstract booklet Background: HIV treatment options remain limited in children. The recent Tivicay (dolutegravir, DTG) pediatric regulatory submissions propose WHO weight-band based recommendations for once-daily dosing in children ≥4 weeks of age using combined datasets from two pediatric studies: IMPAACT P1093 and ODYSSEY (PENTA20). These doses were informed by […]
19
Nov, 2020
European Medicines Agency approves use of Dolutegravir 5 mg dispersible tablet for younger children living with HIV
On November 12th, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending marketing authorisation for dolutegravir 5mg dispersible tablets for young children living with HIV. This decision was based, in part, on data from the ODYSSEY trial. These small tablets can now be used in combination with other medicines for treating children living with HIV who are aged at least four weeks and weigh at least 3kg. CHMP’s positive opinion also supported the updated dosing recommendations for dolutegravir film-coated […]
16
Nov, 2020
International Workshop on HIV Paediatrics 2020: Virtual
This workshop will be focused on the importance of research in paediatric, adolescent, and maternal HIV infections. This type of research is critical to achieving an AIDS-free generation. Unfortunately, children are substantially less likely than adults to be diagnosed, engaged in care, and to access life-saving ART. The HIV Paediatrics Workshop is the only meeting entirely devoted to research in the prevention and treatment of HIV infections in infants, children, and adolescents, making it the premier forum for the world’s leading researchers. Find more information here. Register here.
30
Oct, 2020
COVID and HIV: Psychological impact and awareness of COVID-19 in young people with HIV
Authors: S. Bernardi1, E. Mozzo, M. Di Pastena, F. Leone, C. Novello, A. Oletto, N. Cotugno, P. Zangari, P. Palma, V. Santilli, P. Palma, O. Rampon, C. Giaquinto Published in: 12th National Congress of Italian Conference on AIDS and Antiviral Research Background: Public health emergencies may affect the health, safety, and well-being of both individuals and communities. These effects may translate into a range of emotional reactions and unhealthy behaviours. Some people may be more vulnerable than others to the psychosocial effects of pandemics. Young people living with HIV can […]
17
Sep, 2020
Central and Eastern European Meeting on Viral Hepatitis and HIV
The Central and Eastern European Meeting on Viral Hepatitis and HIV is an independent program, initiated in 2014 and developed by regional and international key opinion leaders for the medical and scientific community in Eastern and Central European countries. The target audience of this meeting consists of healthcare professionals involved in daily care for HCV patients such as infectious disease doctors, gastroenterologists, hepatologists and others. The sixth edition of the Central and Eastern European Meeting on Viral Hepatitis and HIV will be held as a virtual conference. To apply for virtual participation scholarships click here. Click here for […]
9
Sep, 2020
Actual problems of HIV Infection: Mother and Child
Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday 15th September. The Penta session What’s new for children and women living with HIV: interactive clinical day with Penta will look at new data on ART in pregnancy and newborns, resistance and recommendations for 1st, 2nd and further lines, supporting our adolescents and coinfections. Register to conference!
7
Sep, 2020
The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus
Authors: Bollen P, Freriksen J, Konopnicki D, Weizsäcker K , et al; on behalf of the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women Network Published in: Clin infect Dis. 2020;26.ciaa006 Background Pharmacokinetic and efficacy data on dolutegravir in pregnant women living with human immunodeficiency virus (HIV) are still limited but needed to support its use as one of the preferred antiretroviral agents. Methods Within the multicenter Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) study, pregnant women living with HIV and using dolutegravir once daily (50 mg, with food) […]
